Trevor Martin

Co-founder and Chief Executive Officer, Mammoth Biosciences

Search every verified Trevor Martin interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Trevor Martin, co-founder and CEO of Mammoth Biosciences, discussed the potential of CRISPR-based genetic medicine and the role of artificial intelligence in the field during an October 2026 appearance on The Neuron podcast. He described CRISPR as a tool that could turn some lifelong diseases into one-time treatments, and said that with sustained effort, the field could potentially eliminate certain liver or blood genetic diseases within five to ten years. Martin also spoke about Mammoth's work in searching billions of proteins for new editing systems, and noted that AI's usefulness is limited by the quality of biological data available, saying that models "haven't eaten a lot of the key things they need to yet." Martin expressed optimism about the near-term impact of genetic medicine, stating that "we're about to see an explosion of that" and that CRISPR is well-suited for AI applications. He also discussed the challenges of translating preclinical data to clinical outcomes, calling a model that could do so "transformative." Martin acknowledged that biology often reveals unexpected complexity as progress is made, but suggested that even modest improvements in drug development success rates—such as moving from 10% to 20% of drugs entering phase one trials—would be significant. He also commented on the high market valuations of AI companies, drawing an analogy between AI firms potentially entering drug development and a movie-making model company deciding whether to produce films.